Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1990 Sep;71(1):1–9.

Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

S Meri 1, B P Morgan 1, A Davies 1, R H Daniels 1, M G Olavesen 1, H Waldmann 1, P J Lachmann 1
PMCID: PMC1384213  PMID: 1698710

Abstract

Human cells are relatively resistant to lysis by the homologous complement system. Here we describe the mechanism of action of a recently discovered and widely distributed 18,000-20,000 molecular weight (MW) membrane glycoprotein (CD59), which appears to act as a major protective element against complement-mediated lysis (hence called protectin). When incorporated into heterologous erythrocyte membranes, protectin efficiently prevented cell lysis by human serum. Neutralization with antibody of the naturally occurring protectin on human erythrocytes or on nucleated K562 cells increased their susceptibility to lysis by homologous complement. During complement activation, protectin became incorporated into the membrane attack complex (MAC). By interacting with newly exposed regions in the C5b-8 complex and in aggregating C9 it limited the number of C9 molecules associating with the C5b-8 complex to a C8:C9 ratio of 1:1.5 instead of a normal average of 1:3.5. The results demonstrate directly that protectin is a powerful inhibitor of complement cytolysis and acts by inhibiting the C5b-8 catalysed insertion of C9 into the lipid bilayer.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraha A., Morgan B. P., Luzio J. P. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J. 1988 Apr 1;251(1):285–292. doi: 10.1042/bj2510285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bhakdi S., Tranum-Jensen J. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore. J Immunol. 1986 Apr 15;136(8):2999–3005. [PubMed] [Google Scholar]
  3. Dankert J. R., Esser A. F. Proteolytic modification of human complement protein C9: loss of poly(C9) and circular lesion formation without impairment of function. Proc Natl Acad Sci U S A. 1985 Apr;82(7):2128–2132. doi: 10.1073/pnas.82.7.2128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989 Sep 1;170(3):637–654. doi: 10.1084/jem.170.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DiScipio R. G., Chakravarti D. N., Muller-Eberhard H. J., Fey G. H. The structure of human complement component C7 and the C5b-7 complex. J Biol Chem. 1988 Jan 5;263(1):549–560. [PubMed] [Google Scholar]
  6. Groux H., Huet S., Aubrit F., Tran H. C., Boumsell L., Bernard A. A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. Comparison of the roles of H19 and LFA-3 molecules in T cell activation. J Immunol. 1989 May 1;142(9):3013–3020. [PubMed] [Google Scholar]
  7. Hein W. R., Beya M. F. Evidence that the B5 molecule on sheep lymphocytes is a homologue of mouse Ly 6 and human CD59. Immunology. 1989 Dec;68(4):580–582. [PMC free article] [PubMed] [Google Scholar]
  8. Holguin M. H., Fredrick L. R., Bernshaw N. J., Wilcox L. A., Parker C. J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989 Jul;84(1):7–17. doi: 10.1172/JCI114172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lachmann P. J., Thompson R. A. Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med. 1970 Apr 1;131(4):643–657. doi: 10.1084/jem.131.4.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  11. Lichtenheld M. G., Olsen K. J., Lu P., Lowrey D. M., Hameed A., Hengartner H., Podack E. R. Structure and function of human perforin. Nature. 1988 Sep 29;335(6189):448–451. doi: 10.1038/335448a0. [DOI] [PubMed] [Google Scholar]
  12. Morgan B. P., Dankert J. R., Esser A. F. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987 Jan 1;138(1):246–253. [PubMed] [Google Scholar]
  13. Morgan B. P., Daw R. A., Siddle K., Luzio J. P., Campbell A. K. Immunoaffinity purification of human complement component C9 using monoclonal antibodies. J Immunol Methods. 1983 Nov 25;64(3):269–281. doi: 10.1016/0022-1759(83)90434-9. [DOI] [PubMed] [Google Scholar]
  14. Okada H., Nagami Y., Takahashi K., Okada N., Hideshima T., Takizawa H., Kondo J. 20 KDa homologous restriction factor of complement resembles T cell activating protein. Biochem Biophys Res Commun. 1989 Aug 15;162(3):1553–1559. doi: 10.1016/0006-291x(89)90852-8. [DOI] [PubMed] [Google Scholar]
  15. Okada N., Harada R., Fujita T., Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol. 1989;1(2):205–208. doi: 10.1093/intimm/1.2.205. [DOI] [PubMed] [Google Scholar]
  16. Okada N., Harada R., Fujita T., Okada H. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J Immunol. 1989 Oct 1;143(7):2262–2266. [PubMed] [Google Scholar]
  17. Shiver J. W., Dankert J. R., Donovan J. J., Esser A. F. The ninth component of human complement (C9). Functional activity of the b fragment. J Biol Chem. 1986 Jul 25;261(21):9629–9636. [PubMed] [Google Scholar]
  18. Sims P. J. Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage. Biochim Biophys Acta. 1983 Aug 10;732(3):541–552. doi: 10.1016/0005-2736(83)90230-4. [DOI] [PubMed] [Google Scholar]
  19. Sims P. J., Rollins S. A., Wiedmer T. Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem. 1989 Nov 15;264(32):19228–19235. [PubMed] [Google Scholar]
  20. Stanley K. K. The molecular mechanism of complement C9 insertion and polymerisation in biological membranes. Curr Top Microbiol Immunol. 1989;140:49–65. doi: 10.1007/978-3-642-73911-8_5. [DOI] [PubMed] [Google Scholar]
  21. Stefanová I., Hilgert I., Kristofová H., Brown R., Low M. G., Horejsí V. Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol. 1989 Feb;26(2):153–161. doi: 10.1016/0161-5890(89)90097-7. [DOI] [PubMed] [Google Scholar]
  22. Stewart J. L., Monahan J. B., Brickner A., Sodetz J. M. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes. Biochemistry. 1984 Aug 28;23(18):4016–4022. doi: 10.1021/bi00313a002. [DOI] [PubMed] [Google Scholar]
  23. Stewart J. L., Sodetz J. M. Analysis of the specific association of the eighth and ninth components of human complement: identification of a direct role for the alpha subunit of C8. Biochemistry. 1985 Aug 13;24(17):4598–4602. doi: 10.1021/bi00338a018. [DOI] [PubMed] [Google Scholar]
  24. Sugita Y., Nakano Y., Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem. 1988 Oct;104(4):633–637. doi: 10.1093/oxfordjournals.jbchem.a122524. [DOI] [PubMed] [Google Scholar]
  25. Tschopp J. Circular polymerization of the membranolytic ninth component of complement. Dependence on metal ions. J Biol Chem. 1984 Aug 25;259(16):10569–10573. [PubMed] [Google Scholar]
  26. Vogel C. W., Müller-Eberhard H. J. Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods. 1984 Oct 12;73(1):203–220. doi: 10.1016/0022-1759(84)90045-0. [DOI] [PubMed] [Google Scholar]
  27. Whitlow M. B., Iida K., Stefanova I., Bernard A., Nussenzweig V. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol. 1990 Mar;126(1):176–184. doi: 10.1016/0008-8749(90)90310-n. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES